Drugs facing NCE-1 in 2025
1. Amondys 45 patent expiration
AMONDYS 45's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(3 years ago) | |
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(8 months from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(8 months from now) | |
| US8524880 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Apr, 2026
(1 year, 5 months from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(3 years ago) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
2. Apretude patent expiration
APRETUDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 6 months from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
3. Azstarys patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079928 | COMMAVE THERAP | Methylphenidate-oxoacid conjugates, processes of making and using the same |
Jul, 2032
(7 years from now) | |
| US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
| US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
| US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
| US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 07, 2026 |
NCE-1 date: 07 May, 2025
Market Authorisation Date: 07 May, 2021
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE
More Information on Dosage
AZSTARYS family patents
4. Breo Ellipta patent expiration
BREO ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 6 months ago) | |
| US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXO GRP LTD | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7101866 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US7629335 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US6537983 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(3 years ago) | |
| US6759398 | GLAXO GRP LTD | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
| US6878698 | GLAXO GRP LTD | Anti-inflammatory androstane derivatives |
Aug, 2021
(3 years ago) | |
| US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(2 years ago) | |
| US7361787 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 6 months ago) | |
|
US7439393 (Pediatric) | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 1 month from now) | |
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(2 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(2 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Aug, 2028
(3 years from now) | |
| US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(4 years from now) | |
|
US11116721 (Pediatric) | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Aug, 2029
(4 years from now) | |
| US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
| US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(5 years from now) | |
|
US8746242 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a his...
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
5. Bylvay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132416 | IPSEN | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(2 years ago) | |
| US10975046 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10487111 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10981952 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10011633 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10093697 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US9694018 | IPSEN | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(7 years from now) | |
| US11732006 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US11801226 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(14 years from now) | |
| US11802115 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(14 years from now) | |
| US11365182 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(14 years from now) | |
| US11583539 | IPSEN | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-918) | Jun 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating cholestatic pruritus in patients 12 months or older suffering from alagil...
Dosage: CAPSULE; CAPSULE, PELLETS
More Information on Dosage
BYLVAY family patents
6. Cabenuva Kit patent expiration
CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6838464 | VIIV HLTHCARE | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 6 months ago) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(6 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 6 months from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(2 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
7. Corlanor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 4 months from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 4 months from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(1 year, 4 months from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
NCE-1 date: 22 October, 2025
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION
More Information on Dosage
CORLANOR family patents
8. Cosela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10189849 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| US9957276 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| US8598186 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| US8598197 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040042 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Oct, 2031
(7 years from now) | |
| US10927120 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| US10189850 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(7 years from now) | |
| US11717523 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US9487530 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US10966984 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US10085992 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US11529352 | PHARMACOSMOS | Preservation of immune response during chemotherapy regimens |
Jul, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method for reducing the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive-stage small cell lung cancer; A m...
Dosage: POWDER
More Information on Dosage
COSELA family patents
9. Cotellic patent expiration
COTELLIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(5 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(11 years from now) | |
| US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(11 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11597699 | GENENTECH INC | MEK inhibitors and methods of their use |
Oct, 2026
(1 year, 11 months from now) | |
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(1 year, 11 months from now) | |
|
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(2 years from now) | |
|
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(5 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(9 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(10 years from now) | |
|
US10478400 (Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(12 years from now) | |
|
US11254649 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(12 years from now) | |
|
US10590102 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| M(M-278) | Jul 28, 2025 |
| New Indication(I-902) | Oct 28, 2025 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: As a single agent for the treatment of adult patients with histiocytic neoplasms; Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET
More Information on Dosage
COTELLIC family patents
10. Cytalux patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(8 years from now) | |
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(8 years from now) | |
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(8 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(8 years from now) | |
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(8 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-905) | Dec 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2026 |
| Orphan Drug Exclusivity(ODE-390) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 29 November, 2025
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION
More Information on Dosage
CYTALUX family patents
11. Empaveli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(8 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(13 years from now) | |
| US11844841 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Dec, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-288) | Feb 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly; Treatment of adult patients with paroxysmal nocturnal hemoglobinu...
Dosage: SOLUTION
More Information on Dosage
EMPAVELI family patents
12. Exkivity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(10 years from now) | |
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2026 |
| Orphan Drug Exclusivity(ODE-374) | Sep 15, 2028 |
Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient
NCE-1 date: 15 September, 2025
Market Authorisation Date: 15 September, 2021
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: CAPSULE
More Information on Dosage
EXKIVITY family patents
13. Fotivda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2024
(28 days from now) | |
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | Use of tivozanib to treat subjects with refractory cancer |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
14. Halaven patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jun, 2019
(5 years ago) | |
| US6469182 | EISAI INC | Intermediates in the preparation of macrocyclic analogs |
Jun, 2019
(5 years ago) | |
| US7470720 | EISAI INC | Methods and compositions for use in treating cancer |
Jun, 2019
(5 years ago) | |
| US8097648 | EISAI INC | Methods and compositions for use in treating cancer |
Jan, 2021
(3 years ago) | |
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(8 months ago) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(2 years from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Treatment: Treatment of patients with metastatic breast cancer
Dosage: SOLUTION
How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage
HALAVEN family patents
15. Imbruvica patent expiration
IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7514444 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US9181257 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8735403 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8697711 | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8957079 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8008309 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(3 years from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497277 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8952015 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8754091 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8703780 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8476284 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8563563 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(2 years from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8563563 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(3 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(3 years from now) | |
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US8999999 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9801881 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US10751342 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9801883 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9125889 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10016435 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10653696 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9814721 | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US10004746 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10478439 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(8 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(9 years from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(9 years from now) | |
| US10695350 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
| US10463668 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
| US10213386 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US10828259 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US10010507 | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US9655857 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2030 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; Treatment of small lymphocytic lymphoma; Tre...
Dosage: TABLET; CAPSULE
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
16. Jardiance patent expiration
JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(2 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(4 years from now) | |
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(4 years from now) | |
|
US8551957 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Apr, 2030
(5 years from now) | |
| US10406172 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2030
(5 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
17. Jentadueto patent expiration
JENTADUETO's oppositions filed in EPO
JENTADUETO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(1 year, 2 months ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(1 year, 2 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 14 days from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 1 month from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 7 months from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(2 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US10973827 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
|
US10973827 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
| US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(5 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
18. Kerendia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(4 years from now) | |
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
19. Korsuva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
| US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
| US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
| US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION
More Information on Dosage
KORSUVA family patents
20. Leqvio patent expiration
LEQVIO's oppositions filed in EPO
LEQVIO IPR and PTAB Proceedings
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(2 years ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(2 years ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(1 year, 7 months ago) | |
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(11 months ago) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(9 months ago) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(7 months ago) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(7 months ago) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(7 months ago) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(5 months ago) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(2 years from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(2 years ago) | |
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(11 months ago) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(3 years from now) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
21. Livmarli patent expiration
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(6 years from now) | |
| US11229661 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
| US10512657 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| US11918578 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestatis (pfic); Treatment of chole...
Dosage: SOLUTION
More Information on Dosage
LIVMARLI family patents
22. Livtencity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11684632 | TAKEDA PHARMS USA | Maribavir isomers, compositions, methods of making and methods of using |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2026 |
| Orphan Drug Exclusivity(ODE-388) | Nov 23, 2028 |
Drugs and Companies using MARIBAVIR ingredient
NCE-1 date: 23 November, 2025
Market Authorisation Date: 23 November, 2021
Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...
Dosage: TABLET
More Information on Dosage
LIVTENCITY family patents
23. Lumakras patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(13 years from now) | |
| US11827635 | AMGEN INC | Solid state forms |
May, 2040
(15 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| ODE*(ODE*) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET
More Information on Dosage
LUMAKRAS family patents
24. Lupkynis patent expiration
LUPKYNIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
25. Lybalvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7956187 | ALKERMES INC | Method for decreasing opioid metabolism |
Oct, 2021
(2 years ago) | |
| US8252929 | ALKERMES INC | 8-carboxamido-2,6-methano-3-benzazocines |
Oct, 2021
(2 years ago) | |
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(1 year, 1 month from now) | |
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(6 years from now) | |
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
| US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
| US11951111 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan; Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and ...
Dosage: TABLET
More Information on Dosage
LYBALVI family patents
26. Nextstellis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(4 months from now) | |
| US11964055 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(11 years from now) | |
| US11957694 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(11 years from now) | |
| US11793760 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 15 April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET
More Information on Dosage
NEXTSTELLIS family patents
27. Nulibry patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7504095 | SENTYNL THERAPS INC | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
Jan, 2025
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-286) | Oct 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-342) | Feb 26, 2028 |
Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
Dosage: POWDER
More Information on Dosage
NULIBRY family patents
28. Pepaxto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(7 years from now) | |
| US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
More Information on Dosage
PEPAXTO family patents
29. Ponvory patent expiration
PONVORY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2024
(28 days from now) | |
| US9062014 | VANDA PHARMS INC | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | VANDA PHARMS INC | Thiazolidin-4-one-derivatives |
Nov, 2024
(28 days from now) | |
| US8273779 | VANDA PHARMS INC | Thiazolidin 4-one derivatives |
Dec, 2025
(1 year, 1 month from now) | |
| US10220023 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(11 years from now) | |
| US11951097 | VANDA PHARMS INC | Methods of treating multiple sclerosis |
Oct, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET
More Information on Dosage
PONVORY family patents
30. Pylarify patent expiration
PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(3 years from now) | |
| US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(4 years from now) | |
| US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(5 years from now) | |
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(12 years from now) | |
| US11851407 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
More Information on Dosage
PYLARIFY family patents
31. Qelbree patent expiration
QELBREE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(4 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(4 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
QELBREE family patents
32. Qulipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(7 years from now) | |
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
33. Rexulti patent expiration
REXULTI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888362 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 5 months from now) | |
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8349840 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 5 months from now) | |
| US8618109 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 5 months from now) | |
| US9839637 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Apr, 2026
(1 year, 5 months from now) | |
|
US8618109 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 11 months from now) | |
|
US9839637 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 11 months from now) | |
|
US8349840 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 11 months from now) | |
|
US7888362 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Oct, 2026
(1 year, 11 months from now) | |
|
USRE48059 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Jun, 2029
(4 years from now) | |
| US10307419 | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Oct, 2032
(7 years from now) | |
|
US10307419 (Pediatric) | OTSUKA | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Treatment of schizophrenia
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
34. Rezurock patent expiration
REZUROCK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(8 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(8 years from now) | |
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(8 years from now) | |
| US11311541 | KADMON PHARMS LLC | Treatment of GVHD |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus hold disease; For the treatment of chronic graft versus host disease; Treatment of adults and pediatric patients 12 and older with sclerodermatous form of chr...
Dosage: TABLET
More Information on Dosage
REZUROCK family patents
35. Scemblix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(8 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| ODE*(ODE*) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET
More Information on Dosage
SCEMBLIX family patents
36. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(8 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056076 | APELLIS PHARMS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(2 years from now) | |
| US8168584 | APELLIS PHARMS | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Apr, 2027
(2 years from now) | |
| US11903994 | APELLIS PHARMS | Dosing regimens |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
37. Synjardy patent expiration
SYNJARDY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(2 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(4 years from now) | |
| US10610489 | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Sep, 2030
(5 years from now) | |
|
US10610489 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Mar, 2031
(6 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
38. Synjardy Xr patent expiration
SYNJARDY XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(2 years from now) | |
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6488962 | BOEHRINGER INGELHEIM | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(4 years ago) | |
|
US7713938 (Pediatric) | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Oct, 2027
(2 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(4 years from now) | |
| US10596120 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(7 years from now) | |
|
US10596120 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Sep, 2032
(7 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(10 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
39. Tavneos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(5 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(6 years from now) | |
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11951214 | CHEMOCENTRYX | Capsule formulations |
Nov, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE
More Information on Dosage
TAVNEOS family patents
40. Tepmetko patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(3 years from now) | |
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(5 years from now) | |
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(3 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(3 years from now) | |
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET
More Information on Dosage
TEPMETKO family patents
41. Tradjenta patent expiration
TRADJENTA's oppositions filed in EPO
TRADJENTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(1 year, 2 months ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(1 year, 2 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 14 days from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 1 month from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(1 year, 7 months from now) | |
| US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(2 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(2 years from now) | |
|
US11033552 (Pediatric) | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(4 years from now) | |
| US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(4 years from now) | |
|
US10034877 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
|
US9486526 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Feb, 2030
(5 years from now) | |
| US11911388 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Apr, 2030
(5 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(5 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(6 years from now) | |
|
US8853156 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Treatment of type 2 diabetes mellitus; Method of treating type 2 diabetes mellitus by administering li...
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
42. Triumeq patent expiration
TRIUMEQ's oppositions filed in EPO
TRIUMEQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(8 years ago) | |
| US6294540 | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(6 years ago) | |
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(2 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6417191 | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Mar, 2016
(8 years ago) | |
|
US6417191 (Pediatric) | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Sep, 2016
(8 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
|
US6294540 (Pediatric) | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(5 years ago) | |
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
|
US9242986 (Pediatric) | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Jun, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: Treatment of human immunodeficiency virus (hiv) infection.
Dosage: TABLET
How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage
TRIUMEQ family patents
43. Truseltiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(3 years from now) | |
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) | |
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TRUSELTIQ family patents
44. Ukoniq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(10 years from now) | |
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(8 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...
Dosage: TABLET
More Information on Dosage
UKONIQ family patents
45. Verquvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET
More Information on Dosage
VERQUVO family patents
46. Vocabria patent expiration
VOCABRIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(1 year, 6 months from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR SODIUM ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: TABLET
More Information on Dosage
VOCABRIA family patents
47. Voxzogo patent expiration
VOXZOGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(5 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(11 years from now) | |
| US11911446 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(11 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(11 years from now) | |
| US11590204 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 19, 2026 |
| Orphan Drug Exclusivity(ODE-387) | Nov 19, 2028 |
| Orphan Drug Exclusivity(ODE-449) | Oct 20, 2030 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: 19 November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia with open epiphyses
Dosage: POWDER
More Information on Dosage
VOXZOGO family patents
48. Welireg patent expiration
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| USRE49948 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Dosage: TABLET
More Information on Dosage
WELIREG family patents
49. Zegalogue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE family patents
50. Zegalogue (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE (AUTOINJECTOR) family patents